Focus Partners Advisor Solutions’s Madrigal Pharmaceuticals MDGL Stock Holding History

Focus Partners Advisor Solutions’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.84M	Buy	+3,647	New	+$1.93M	0.01%	530

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Focus Partners Advisor Solutions's MDGL Position: Q3 2026 in Review

Focus Partners Advisor Solutions opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 3,647 shares worth $1.84M. The stake represents 0.01% of the portfolio and ranks #530 among its holdings.

226 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Focus Partners Advisor Solutions held 3,647 shares of Madrigal Pharmaceuticals worth $1.84M as of Q3 2026.
Madrigal Pharmaceuticals was a new Focus Partners Advisor Solutions position in Q3 2026.
Madrigal Pharmaceuticals made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q3 2026, its #530 holding.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2026, filed 10 Nov 2026.